Fig. 6: Colon-specific mTOR inhibition improves insulin secretion capacity.
From: Targeting colonic macrophages improves glycemic control in high-fat diet-induced obesity
Wild-type mice were fed a coconut-based HFD for 1 week (wk) and treated intrarectally with 3 mg/kg rapamycin (purple rhombus) or vehicle (red circles): a Geometric mean fluorescent intensity (gMFI) of phosphorylated S6 (pS6) and Akt (pS473) in colonic macrophages (c-Macs). b gMFI of MitoSOX in c-Macs. c–e gMFI of pS6 in adipose tissue macrophages (ATMs) (c), splenic monocytes (d) and peritoneal macrophages (small: SPM/large: LPM) (e). f Intraperitoneal glucose tolerance test (IPGTT: vehicle n = 10, rapamycin n = 13), body weight, and insulin levels at IPGTT, and insulin tolerance test (ITT: vehicle n = 18, rapamycin n = 16). g Basal and glucose-stimulated insulin secretion (GSIS) in islets ex vivo. Data are representative of one (b, g) experiment or two (a, f GTT), three (d–f ITT), or four (c) independent experiments, with each data point representing one individual mouse. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired Mann–Whitney U test with two-tailed distribution.
